Protips: Plasmablasts are made after B cell activation, making dsDNAAb & NMDA Ab that bind complement forming IC’s. A drug targeting plasmablast may be a better target. Belimumab may work better for short-lived B cell problems. – Dr. M Kahlenberg @rheumnow #RNL2024 https://t.co/vj6sRn4f7c